Pulmonary Issues- Critical Care Review - PowerPoint PPT Presentation

1 / 54
About This Presentation
Title:

Pulmonary Issues- Critical Care Review

Description:

Eli Lilly and Company, US Medical. 5-14-04 Eli Lilly and Company, US Medical. 5-14-04 * * Establishing vascular access and initiating aggressive fluid ... – PowerPoint PPT presentation

Number of Views:151
Avg rating:3.0/5.0
Slides: 55
Provided by: wfdSssih
Category:

less

Transcript and Presenter's Notes

Title: Pulmonary Issues- Critical Care Review


1
Pulmonary Issues- Critical Care Review
  • Akella Chendrasekhar MD FACS FCCP

2
When do you start your antibiotics for VAP?
  1. Upon clinical suspicion empiric
  2. After Gram stain data is obtained
  3. After cultures data is obtained and verified
  4. I have all my intubated patients on antibiotics
    regardless of clinical presentation

3
Presumptive antibiotic treatment based on gram
staining reduced the incidence of ARDS in
mechanically ventilated patients
  • Asako Matsushima, MD, Osamu Tasaki, MD, Kentaro
    Shimizu, MD, Kazunori Tomono, MD,
  • Hiroshi Ogura, MD, Takeshi Shimazu, MD, and
    Hisashi Sugimoto, MD
  • J Trauma. 200865309 315.

4
Methods
  • Inclusion criteria
  • Patients intubated for more than 72 hours
  • All patients enrolled in this study underwent
    emergency intubation without any preparation such
    as oral care or fasting
  • Exclusion criteria
  • Patients less than age 16
  • Patients who suffered brain death
  • Patients who were intubated for planned operation

5
2 study groups
  • 2 time periods
  • First period VAP diagnosed by ATS guidelines
  • The presence of a new or progressive radiographic
    infiltrate plus at least two of three clinical
    features (fever greater than 38C, leukocytosis
    or leukopenia, and purulent secretion).
  • 2nd time period-bedside gram staining of purulent
    tracheobronchial secretions of patients with high
    fever (greater than 38C) or leukocytosis, and
    started antibiotic treatment if bacterial
    phagocytosis was seen under the microscope even
    before lung infiltration was seen on a chest
    X-ray film.

6
2nd group
7
(No Transcript)
8
(No Transcript)
9
(No Transcript)
10
Antibiotics used
11
Pathogens
12
Conclusions
  • In this 2-phase study, a more aggressive
    antibiotic regimen based upon Grams stain
    results and despite the absence of infiltrates on
    CXR was associated with a several-fold reduction
    in incidence of ARDS and VAP without increased
    using more antibiotics.

13
SEPSIS
14
Tiered System of Progressively More Severe
Inflammatory States (ACCP)
  • SIRS 2 or more of the following mortality 7
  • Temp gt 38 C or lt36 C
  • HR gt 90/min
  • RR gt20/min, PaCO2 lt 32 mmHg
  • WBC gt 12K, lt 4K or gt10 bands
  • Sepsis SIRS compelling evidence of infection
    mortality 16
  • Severe Sepsis Sepsis At least 1 end organ
    dysfunction mortality 20
  • Septic Shock Severe Sepsis Hypotension
    refractory to volume expansion mortality 46

15
Early Goal Directed Therapy in Sepsis-
  • I follow the EGDT guidelines in the management of
    ALL of my patients in sepsis or severe sepsis
  • I follow the EGDT guidelines for the management
    of MOST of my patients in septic shock or severe
    sepsis
  • I do not follow any EGDT guidelines routinely.

16
Initial Resuscitation
  • Resuscitation should begin as soon as severe
    sepsis or sepsis induced tissue hypoperfusion is
    recognized
  • Elevated Serum lactate identifies tissue
    hypoperfusion in patients at risk who are not
    hypotensive
  • Goals of therapy within first 6 hours are
    Grade B
  • Central Venous Pressure 8-12 mm Hg (12-15 in
    ventilator pts)
  • Mean arterial pressure gt 65 mm Hg
  • Urine output gt 0.5 mL/kg/hr
  • ScvO2 or SvO2 70 if not achieved with fluid
    resuscitation during first 6 hours
    - Transfuse PRBC to hematocrit gt 30 and/or
    - Administer dobutamine (max 20 mcg/kg/min)
    to goal

-
Rivers E. N Engl J Med 20013451368-77.
Dellinger, et. al. Crit Care Med 2004, 32
858-873.
17
Early Goal-Directed Therapy Results
28-day Mortality
60
49.2
P 0.01
50
40
33.3
30
20
10
0
Standard Therapy n133
EGDT n130
Key difference was in sudden CV collapse, not
MODS
Rivers E. N Engl J Med 20013451368-77.
18
How do you manage fluids in patients with sepsis
and acute lung injury ?
  1. Liberal with fluids using mostly crystalloids
  2. Liberal with fluids using mostly colloids
  3. Conservative with fluids
  4. Fluid management irrelevant as pt is on ventilator

19
The importance of fluid management in acute lung
injury secondary to septic shock.
  • Murphy, C. V., Schramm, G. E., Doherty, J. A.,
    Reichley, R. M., Gajic, O., Afessa, B., et al.
    (2009). Chest, 136(1), 102-109.

20
Methods
  • Retrospective analysis
  • Primary outcome parameter- hospital mortality
  • Patients with septic shock were identified by
    diagnostic codes
  • patients with ALI were also identified using
    chest radiograph reports, Pao2/fraction of
    inspired oxygen (Fio2) ratio, the requirement for
    mechanical ventilation, and medical record and
    available echocardiographic data indicating the
    absence of acute cardiac disease as the etiology
    for the pulmonary infiltrates

21
Methods
  • Location - Barnes-Jewish Hospital (St. Louis, MO)
    and in the medical ICU of Mayo Medical Center
    (Rochester, MN).
  • Adequate initial fluid resuscitation-AIFR
    administration of an initial fluid bolus of gtor
    20 mL/kg prior to and achievement of a central
    venous pressure of gtor 8 mmHg within 6 h after
    the onset of therapy with vasopressors. early
    goal directed therapy
  • Conservative late fluid management (CLFM)
    even-to-negative fluid balance measured on at
    least 2 consecutive days during the first 7 days
    after septic shock onset.

22
Methods
  • Study Cohort- 212patients with septic shock who
    developed acute lung injury
  • Compared survivors to non-survivors to see what
    impacted on mortality.

23
(No Transcript)
24
(No Transcript)
25
(No Transcript)
26
(No Transcript)
27
ACUTE LUNG INJURY
28
44 year old male presents with acute lung injury
after trauma how would you manage the patient ?
  1. Liberal fluid provision throughout the hospital
    course
  2. Conservative keep the patient hypovolemic
    throughout fluid management
  3. Liberal fluid provision initially followed by
    conservative fluid management
  4. I am not sure

29
Less Is More Improved Outcomes in Surgical
Patients with Conservative Fluid Administration
and Central Venous Catheter Monitoring
  • Presented at the Southern Surgical Association
    120th Annual Meeting, West Palm Beach, FL,
    December 2008.Ronald M. Stewart MD, FACSa, ,
    Pauline K. Park MD, FACSb, John P. Hunt MD,
    FACSc, Robert C. McIntyre Jr MD, FACSd, Janet
    McCarthy RNa, Lee Ann Zarzabal MSa, Joel E.
    Michalek PhDe and NIH/NHLBI ARDS Clinical Trials
    Network

30
Methods
  • The ARDS Clinical Trials Network Fluid and
    Catheter Treatment Trial (FACTT) addressed fluid
    management and central monitoring of patients
    with acute respiratory distress syndrome/acute
    lung injury (ARDS/ALI).
  • Posthoc, surgical subgroup analysis of 1,000
    patients enrolled in the FACTT.
  • 244 surgical patients

31
(No Transcript)
32
(No Transcript)
33
The conservative fluid-management group had
significantly more negative fluid balance at day
7.
34
There were more ventilator-free days with
conservative fluid management and no difference
in dialysis-free days with liberal or
conservative fluid.
35
Results
  • Risk of death within 60 days of randomization did
    not vary with catheter or fluid management, and a
    corresponding lack of effect was evident with
    regard to dialysis-free day.

36
Steroids in sepsis
37
A 50 year old female presents with septic shock
do you use steroids ?
  1. Yes high dose
  2. Yes low dose
  3. No
  4. Not sure what to do.

38
Steroids
Grade C
  • Intravenous corticosteroids are recommended in
    patients with septic shock who require
    vasopressor therapy to maintain blood pressure
  • Administer intravenous hydrocortisone 200-300
    mg/day for 7 days in three or four divided doses
    or by continuous infusion
  • Shown to reduce mortality rate in patients with
    relative adrenal insufficiency

Annane, D. JAMA, 2002 288 (7) 868
Dellinger, et. al. Crit Care Med 2004, 32
858-873.
39
Steroids
  • May use 250 mcg ACTH stimulation test to identify
    responders and discontinue therapy in these
    patients
  • Responders can be defined as gt9 mcg/dL increase
    in cortisol 30-60 minutes post ACTH
    administration
  • Clinicians should not wait for ACTH stimulation
    test results to administer corticosteroids
  • After the resolution of septic shock, may
    decrease dosage of steroids
  • Consider tapering the dose of corticosteroids at
    the end of therapy
  • May add fludrocortisone to the hydrocortisone
    regimen

Grade E
Annane, D. JAMA, 2002 288 (7) 868
Dellinger, et. al. Crit Care Med 2004, 32
858-873.
40
Steroids
Low-Dose Steroids 28-day Mortality
Patients with Relative Adrenal Insufficiency
(ACTH Test Non-responders) (77)
Patients Without Relative Adrenal Insufficiency
(ACTH Test Responders) (23)
P0.04
P0.96
28-day Mortality
N114
N36
N34
N115
Annane, D. JAMA, 2002 288 (7) 868
41
Steroids
Grade A
  • Doses of hydrocortisone gt300 mg daily should NOT
    be used in septic shock or severe sepsis for the
    purpose of treating shock
  • In the absence of shock, corticosteroids should
    not be used for treatment of sepsis

Grade E
Bone RC. N Engl J Med 1987653-658. VA Systemic
Sepsis Cooperative Study Group. N Engl J Med
1987317659-665.
Dellinger, et. al. Crit Care Med 2004, 32
858-873.
42
Original Article Hydrocortisone Therapy for
Patients with Septic Shock
Charles L. Sprung, M.D., Djillali Annane, M.D.,
Ph.D., Didier Keh, M.D., Rui Moreno, M.D., Ph.D.,
Mervyn Singer, M.D., F.R.C.P., Klaus Freivogel,
Ph.D., Yoram G. Weiss, M.D., Julie Benbenishty,
R.N., Armin Kalenka, M.D., Helmuth Forst, M.D.,
Ph.D., Pierre-Francois Laterre, M.D., Konrad
Reinhart, M.D., Brian H. Cuthbertson, M.D.,
Didier Payen, M.D., Ph.D., Josef Briegel, M.D.,
Ph.D., for the CORTICUS Study Group
N Engl J Med Volume 358(2)111-124 January 10,
2008
43
Study Overview
  • The benefit of adjuvant use of corticosteroids in
    patients with septic shock remains controversial
  • In this international, multicenter, double-blind,
    placebo-controlled trial, adjunctive therapy with
    hydrocortisone in nearly 500 patients with septic
    shock was not found to be clinically helpful
  • This lack of benefit was also found in a subgroup
    of patients who did not have a response to a
    corticotropin test

44
Enrollment and Outcomes
Sprung CL et al. N Engl J Med 2008358111-124
45
Demographic Characteristics of the Patients,
According to Subgroup
Sprung CL et al. N Engl J Med 2008358111-124
46
Clinical Characteristics of the Patients at
Baseline, According to Subgroup
Sprung CL et al. N Engl J Med 2008358111-124
47
Kaplan-Meier Curves for Survival at 28 Days
Sprung CL et al. N Engl J Med 2008358111-124
48
Outcomes According to Subgroup
Sprung CL et al. N Engl J Med 2008358111-124
49
Kaplan-Meier Curves for the Time to Reversal of
Shock
Sprung CL et al. N Engl J Med 2008358111-124
50
Adverse Events (Per-Protocol Population)
Sprung CL et al. N Engl J Med 2008358111-124
51
Conclusion
  • Hydrocortisone did not improve survival or
    reversal of shock in patients with septic shock,
    either overall or in patients who did not have a
    response to corticotropin, although
    hydrocortisone hastened reversal of shock in
    patients in whom shock was reversed

52
H1N1 Influenza
  • CDC REPORT

53
Epidemiology
  • 122 countries 94,512 cases reported
  • 429 fatal
  • Rapidly progressive lower respiratory tract
    disease
  • Development of ARDS
  • Prolonged ICU admission
  • Focused review of 10 consecutive patients with
    severe ARDS and H1N1 infection seen at a
    tertiary care center in michigan, USA

54
Clinical characteristics
  • 90 - BMI greater than or equal to 30
  • 70 -BMI greater than 40
  • 50 - pulmonary emboli
  • 90 - Multiple organ dysfunction
  • 30 mortality
Write a Comment
User Comments (0)
About PowerShow.com